Corticosteroid Withdrawal Precipitates Perilesional Edema around Calcified Taenia solium Cysts

Rojelio Mejia and Theodore E. Nash*

Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas; Gastrointestinal Parasites Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Abstract. Calcified Taenia solium granulomas are the focus of repeated episodes of perilesional edema and seizures in 50% of persons with calcifications, history of seizures, and a positive serology for cysticercosis. The pathophysiology is unclear but recent studies suggest the edema is caused by inflammation. We report two new cases and four other published cases where cessation of corticosteroids appeared to result in recurrence or new appearance of perilesional edema around calcifications. This suggests that perilesional edema is an immune-mediated phenomenon.

INTRODUCTION

Neurocysticercosis is an infection of the larval cyst stage of the cestodes, Taenia solium and is responsible for 29% of epilepsy in endemic areas worldwide.1 Humans harbor the adult tapeworm in the small intestine, which consists of a head, neck, and a long array of increasingly mature segments or proglottids each containing 30,000–50,000 infectious ova released in the feces as liberated ova or proglottids. After ingestion of ova in feces by pigs or after the accidental ingestion of ova from contaminated hands or in food or water by humans, the developing oncospheres migrate into the blood stream, lodge in tissues throughout the body but mostly develop into viable cysts in the brain, muscles, and subcutaneous tissues. Tapeworms develop after ingestion of undercooked pork by humans, fulfilling the life cycle.2

Viable parenchymal cysts incite little inflammation until recognized by the host, which commonly results in cyst degeneration and seizures. The end-stage granuloma, consisting of varying amounts of host inflammatory cells and degenerated cyst components, frequently calcifies resulting in typical calcifications on computed tomography (CT) imaging. Recent studies indicate calcifications are important foci of seizure activation.3,4 The presence of enhancement around a subset of calcifications5–9 the episodic occurrence of perilesional edema and seizure activity localized to some calcifications,3,4,10 and the presence of significant inflammation in two excised lesions11 (Nash and others, in preparation), strongly suggest the continued presence of inflammation associated with a subset of calcifications. This hypothesis implies that immune responses are periodically induced, perhaps by intermittent antigen release10 or after episodic loss of suppressive immune inhibition, or some combination of both.

We describe two patients who developed perilesional edema around calcifications in the setting of corticosteroid withdrawal after treatment of parenchymal neurocysticercosis. We reviewed four similar cases (Table 1) whose histories suggest the presence of perilesional edema was initiated in the setting of corticosteroid withdrawal after treatment.

CASE REPORT

Patient 1. A 28-year-old man from Guatemala presented to a local hospital with a 2-day history of progressive right arm and leg weakness and a constant left sided headache. An initial CT and magnetic resonance imaging (MRI) revealed a large cyst occupying the left motor strip (Figure 1B). Because of the size of the cyst, the large degree of edema and worsening neurologic condition, this lesion was excised. Furthermore, visualized on imaging was a small single round calcified lesion in the right parietal lobe (Figure 1B), a viable cyst in the left parietal convexity (not shown), and a large calcified lesion in the Sylvian fissure (Figure 1A), abutting upon the left frontotemporal lobe. He was treated with a 10-day course of albendazole 800 mg every 12 hours and 10 days of dexamethasone 16 mg daily with a short taper and levetiracetam 500 mg twice a day. Four days after stopping steroids, the patient began to have fevers of 101°F, increasing the left sided headaches and decreasing strength of the right extremities.

On his initial visit to National Institutes of Health (NIH), 24 days after initial hospitalization and 9 days after he developed fever, follow-up MRI and CT examinations (Figure 1E–H) unexpectedly revealed that the two previously quiescent calcified lesions developed significant perilesional edema and enhancement (Figure 1E–H). The prior viable cysts were degenerating and the edema surrounding the excised cyst had decreased (not shown). He was restarted on corticosteroids. His symptoms resolved on a slow taper of corticosteroids and serial MRI’s showed gradual improvement. The patient subsequently developed another spontaneous perilesional edema episode involving the Sylvian fissure calcification about 1.5 years later (images not shown).

Patient 2. A 34-year-old female was well until September 22, 1998 when she suddenly experienced left leg shaking followed by a generalized seizure. Another focal seizure involving only the left leg occurred 5 days later. A series of CT and MRI scans revealed a single circular enhancing edematous non-calcified lesion in the medial frontal aspect of the right frontal lobe (not shown). A brain abscess was suspected and the patient was treated with phenytoin and 8 weeks of intravenous antibiotics. A follow-up MRI 1 month later, showed the perilesional edema had disappeared, but enhancement persisted (not shown). An informal opinion by NIH at the request of her caring physicians suggested that neurocysticercosis was a possibility prompting a serological examination at a commercial laboratory, which was subsequently...
positive. A second positive serology confirmed the results of the first test. She was treated with a 14-day course of albendazole and corticosteroids in November of 1998. The NIH was officially consulted on June 19, 1999. An MRI at this date did not show perilesional edema (Figure 2A) and a Western blot serology for cysticercosis, performed at the Centers for Disease Control and Prevention (CDC) was positive. She did well for about the next 6 months, but on 1/9/2000 focal seizures of the left foot reoccurred and imaging revealed the reappearance of perilesional edema around the lesion (not shown) prompting a course of high dose corticosteroids. Subsequently, on 1/27/2000 the patient, who by this time was asymptomatic, was reevaluated at NIH. A CT scan revealed a small calcification had developed within the lesion (Figure 2F) and the associated edema had decreased considerably (Figure 2B). The lesion became densely calcified over the next 14 months (Figure 2G). Shortly after the corticosteroids were stopped, on 2/12–14/2000 numbness of the face, left foot focal seizures, and perilesional edema around the calcification reoccurred. High dose corticosteroids were restarted by her private physician and the patient was subsequently reevaluated at NIH on 2/28/2000. The patient was asymptomatic and MRI imaging showed persisting perilesional edema (Figure 2C). By 3/14/2000, perilesional edema was no longer present and the patient was weaned off corticosteroids on 4/12/2000. However, the next day on 4/13/2000 (Figure 2D) the patient again experienced focal seizures involving the left foot and the reappearance of perilesional edema around the lesion. The

### Table 1

Summary of cases with perilesional edema induced by corticosteroid withdrawal or summary of cases

<table>
<thead>
<tr>
<th>Case number</th>
<th>Age (year), sex (reference)</th>
<th>Known calcifications</th>
<th>Context</th>
<th>Relation to steroid taper</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>37 y/o F [12]</td>
<td>Yes</td>
<td>Treated 7 years earlier, proven calcifications without edema</td>
<td>Stopped 7 days earlier</td>
</tr>
<tr>
<td>2</td>
<td>8 y/o F [13]</td>
<td>Yes, documented asymptomatic calcifications</td>
<td>Developed symptomatic pons enhancing lesion</td>
<td>Within 1 week</td>
</tr>
<tr>
<td>3</td>
<td>48 y/o F [5,14]</td>
<td>Yes, 55 calcifications</td>
<td>Multiple episodes of perilesional edema</td>
<td>2 days after taper</td>
</tr>
<tr>
<td>4</td>
<td>43 y/o F [15]</td>
<td>Yes</td>
<td>Viable cyst and calcification, undergoing anthelmintic and corticosteroids treatment</td>
<td>Stopped 10 days earlier, multiple calcifications with edema</td>
</tr>
<tr>
<td>5</td>
<td>34 y/o F (Mejia and Nash 2013)</td>
<td>Yes</td>
<td>Viable single cyst that calcified after treatment. Multiple seizure episodes during taper or after stopping</td>
<td>1 and 6 days after completing taper</td>
</tr>
<tr>
<td>6</td>
<td>28 y/o M (Mejia and Nash 2013)</td>
<td>Yes</td>
<td>Treatment of viable cysts with 2 known previous calcifications without enhancement or edema</td>
<td>4 days after stopping steroids</td>
</tr>
</tbody>
</table>

MRI = magnetic resonance imaging.

---

**Figure 1.** Patient 1: Magnetic resonance imaging (MRI) and computed tomography (CT) images at presentation (A–D) and initial evaluation at National Institutes of Health (NIH) (E–H). (A and B) show calcifications in the left Sylvian fissure (A) and right parietal (B) region without perilesional edema on MRI fluid attenuated inversion recovery (FLAIR) sequences, (C and D), respectively. (B) A mass is present in the left motor strip with massive edema that differs in location from the Sylvian fissure calcification. (E) and (F) are MRI FLAIR sequences showing the development of edema and enhancement (G and H, MRI T1 with gadolinium) around both calcifications.
perilesional edema resolved by 5/05/2000 (not shown). Over
the next 2 years, despite appropriate anti-seizure medication,
the patient experienced multiple episodes consisting of various
combinations of focal seizures of the left foot, dysesthesias of
the face and/or left side of the body accompanied by the
reappearance of perilesional edema. Episodes, which were
treated with high-dose corticosteroids followed by a taper,
resulted in regression of perilesional edema and disappearance
of focal seizures followed by repeated episodes when steroids
were decreased or stopped. Perilesional edema was again
documented on 8/28/2002 (Figure 2E) following evaluation for
focal left foot seizures. Eventually, following a taper lasting
months, recurrent seizures did not reoccur when corticoste-
roids were stopped. The patient was lost to follow-up.
Although the patient had traveled widely in the United States
and Europe, there was no travel to Latin America or known
demic regions. Furthermore, there was no history of more
than casual contact with persons from endemic regions includ-
ing domestic employees nor was there a history of ingestion of
exotic or likely contaminated food.

RESULTS

Both of the newly reported cases and the four previously
published reports (Table 1) show a clear association between
stopping and/or tapering corticosteroids and new presence of
perilesional edema associated with symptoms. Case 1 (Table 1)
was a 37 y/o female who developed headache, nausea,
vomiting, and decreased mentation 1 week after completing
a 5-day course of corticosteroids for erythema nodosum.12
She had presented about 9 years earlier with seizures and
multiple viable parenchymal cysts caused by T. solium. Subse-
quently, she required a ventriculoperitoneal shunt for hydro-
cephalus and was treated successfully with albendazole for
multiple parenchymal cysts that had all calcified 4 years before
her present illness. The MRI and CT showed edema and
increased enhancement and edema around three of the calcifi-
cations. Prior imaging, the latest 3 months earlier, revealed
enhancement but no edema around the same calcifications.

Case 2 presented with esotropia caused by an enhancing
calcification in the left pons.13 Multiple calcifications caused
by neurocysticercosis were incidentally documented following
brain imaging for minor head trauma about 3 years earlier.
She experienced multiple episodes of perilesional edema
around the left pons calcification, some of which clearly
occurred shortly after stopping corticosteroids. In addition,
parenchymal calcifications changed from non-enhancing to
enhancing lesions in at least one episode. Case 3, who was
previously reported, was followed prospectively because of
recurring seizures, most commonly associated with intermit-
tent perilesional edema, around a subset of 55 calcifications.5,14
Perilesional edema episodes were initially treated
with high-dose dexamethasone followed by tapers of varying
duration. Over a 4-year period she experienced 12 clinical
episodes of seizures or focal neurological deficits, 6 of which
occurred during the taper just after stopping steroids. Most
recurrent episodes of perilesional edema occurred when the
patient was tapered from 16 mg/dexamethasone. Episodes
were documented at dosages during the steroid taper of 5 mg
every other day, 0.5 mg every other day, 3 mg/day, and 2 days
after completing a taper.

Poeschl and others15 reported an individual (case 4) who
developed perilesional edema around 8 calcifications 8 days
after completion of a course of albendazole and cortico-
steroids for treatment of viable cysts. Earlier imaging docu-
mented neither edema nor enhancement associated with
these calcifications.

The timing of perilesional associated with taper or cessation
of corticosteroid varied from during the taper to 4 weeks after
stopping corticosteroids. Some of the variability may be the
result of difficulty in recognizing the beginning of symptoms
and delay in obtaining confirmatory MRIs. Although it is
possible those spontaneously occurring perilesional edema
episodes could randomly coincide with decreased or cessation
of corticosteroid dosing, the repetitive association of symptoms and perilesional edema is compelling. Five of the six patients with more than one calcification showed perilesional edema involving multiple calcifications that suggests a mechanism(s) not inherently limited to a specific lesion (Table 1). On the other hand, spontaneously occurring perilesional edema episodes may occur repeatedly around one calcification or a small subset of calcifications.

**DISCUSSION**

Perilesional edema around calcifications occurs spontaneously in 50% of persons in endemic regions with a history of seizures, with only calcifications and a positive serology for *T. solium* infection. The association between cessation or decrease in corticosteroids during a taper of drug dosing, which is commonly administered to lessen symptoms caused by brain edema of any cause including neurocysticercosis, was unexpected. We observed a close association in our patients and subsequently realized that a number of reports in the literature were in fact unrecognized examples of perilesional edema events worsened or initiated after cessation or dose lowering during the taper of corticosteroids. This association was previously unappreciated. Although in some instances albendazole was administered along with corticosteroids, several lines of evidence suggest the decrease in corticosteroids and not administration of albendazole triggered perilesional edema episodes. Albendazole administrative has no effect on calcified cysts. When antihelmintics were first used, treatment with praziquantel was routinely used because of the possibility of live non-visualized cysts in patients with only calcifications. No induced inflammation occurred (Nash T, personal communication), which is consistent with the general knowledge that calcifications are dead cysts (Nash and others, in preparation); additionally, albendazole was not always given and therefore could play no role in the process. In three of the six cases, albendazole was only administered after the initial presentation, and in one patient was not administered before one of several episodes. The histopathology of two calcified lesions associated with repeated episodes does not show live or viable parasite (Nash and others, in preparation). Therefore, corticosteroids are implicated because its administration was invariably associated with one or more episodes, whereas albendazole was variably given before perilesional edema episodes occurred and does not affect dead cysts.

There are two favored hypotheses of the causative mechanism(s), an immune inflammatory cause and edema following seizure activity. Currently, most of the evidence favors inflammatory mechanisms. Although a few calcified lesions have been described as grossly chalky white lesions containing little host response and sometimes recognized parasite remnants; nevertheless, a subset of calcifications appear to be associated with inflammation. Enhancement is frequently seen around some calcifications suggesting the presence of enough inflammation to cause blood brain barrier disruption; the histopathology of calcified lesions is sparse. A few illustrations in texts indicate little on-going inflammation, which is contrasted with the histological descriptions of the entire calcified lesion surgically removed from two patients with episodes of perilesional edema. The calcified lesions showed significant mononuclear inflammatory reaction. Activation of microglial astrocytes and monocytes has also been measured using a ligand to translocator protein 18 kDa in patients with recent episodes of perilesional edema. There was a significant increase in uptake in the affected regions indicating the presence of inflammation. Furthermore, the presence of calcification in a lesion does not exclude the presence of inflammation. In patient 2, the *T. solium* granuloma was imaged frequently and showed gradual calcification. Even though there was a small amount of calcification, the granuloma behaved very much like the previously non-calcified granuloma. It is likely that some calcified lesions, for reasons that are unclear, still maintain a certain degree of inflammation causing blood brain barrier dysfunction and enhancement and a propensity to cause perilesional edema. Inflammation as a result of non-calcified degenerating lesions is caused by host immune response to parasite antigen, which may wax and wane in intensity sometimes resulting in seizures or focal symptoms. The episodic appearance of inflammation and edema around calcified cysts is reminiscent of degenerating non-calcified cysts and suggests a similar pathophysiological mechanism, which could be either intermittent release or recognition of parasite antigen by the host or periodic loss of immune suppression.

The second favored hypothesis is edema, which occurs secondary to seizure activity. Several lines of evidence do not favor this idea. The edema following seizures is mostly described in persons with status epilepticus. Most patients with perilesional edema in calcific disease do not develop status epilepticus and even 10% are asymptomatic. Electroencephalographs are usually not abnormal in the few perilesional edema patients studied close to the presenting seizure (Nash T, personal communication). The edema associated with seizure activity is diffuse and not angiogenic, which is the pattern in perilesional edema, finally, perilesional edema is a relatively common event in calcified neurocysticercosis. The edema caused by seizures in epilepsy appears to be less common. Another possibility is inflammation will be partially decreased with steroids, but will revert to its initial degree as the steroids are tapered as may have occurred in some episodes in case 2. However, in cases 1, 4, 6, and some episodes of cases 2 and 3, perilesional edema was not present initially, but became evident after stopping corticosteroids. Although it is conceivable that corticosteroids could result in remodeling of the calcification and release of antigen, a hypothesized unproven mechanism, it may be more likely that corticosteroids causes transient loss of immune suppression that results in overt inflammation and edema. If true, seizures caused by perilesional edema may be controlled by manipulation of the immune system.

Received June 12, 2013. Accepted for publication July 31, 2013. Published online September 3, 2013.

Financial support: This study was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases; U.S. National Institutes of Health.

Authors’ addresses: Rojelio Mejia, Baylor College of Medicine, National School of Tropical Medicine, Houston, TX, and National Institute of Allergy and Infectious Diseases, Laboratory of Parasitic Diseases, Bethesda, MD, E-mail: rojelio.mejia@bcm.edu. Theodore E. Nash, National Institute of Allergy and Infectious Diseases, Laboratory of Parasitic Diseases, Bethesda, MD, E-mail: tnash@niaid.nih.gov.
REFERENCES


